Microparticle Shedding by Erythrocytes, Monocytes and Vascular Smooth Muscular Cells Is Reduced by Aspirin in Diabetic Patients;El ácido acetilsalicílico reduce la liberación de micropartículas eritrocitarias, monocitarias y de células del músculo liso vascular en pacientes diabéticos

Revista Espanola de Cardiologia

Volumn 69, Issue 7, 2016, Pages 672-680

  Chiva Blanch, Gemma ^a   Suades, Rosa ^a   Padró, Teresa ^a   Vilahur, Gemma ^a   Peña, Esther ^a   Ybarra, Juan ^b   Pou, Jose M ^c   Badimon, Lina ^a  

^a Institut Català de Ciències Cardiovasculars   (Spain)

^b CENTRO MÉDICO TEKNON   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Activated cells; Aspirin; Circulating cell derived microparticles; Diabetes mellitus; Tissue factor

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; THROMBOPLASTIN; THROMBOXANE; ANTITHROMBOCYTIC AGENT;

ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CIRCULATION; CLINICAL ARTICLE; DIABETIC PATIENT; DRUG EFFICACY; ENDOTHELIAL MICROPARTICLE; ERYTHROCYTE; FLOW CYTOMETRY; HEART PROTECTION; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; INTERVENTION STUDY; LEUKOCYTE ACTIVATION; MEMBRANE MICROPARTICLE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLATELET MICROPARTICLE; THROMBOCYTE LIFESPAN; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE CELL; ADULT; AGED; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; THROMBOCYTE; THROMBOCYTE ACTIVATION; VASCULAR SMOOTH MUSCLE;

ADULT; AGED; ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CELL-DERIVED MICROPARTICLES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ERYTHROCYTES; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOCYTES; MUSCLE, SMOOTH, VASCULAR; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS;

EID: 84978143568     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2015.12.034     Document Type: Article

References (34)

1. 1 Fox, C.S., Coady, S., Sorlie, P.D., D'Agostino, R.B. Sr., Pencina, M.J., Vasan, R.S., et al. Increasing cardiovascular disease burden due to diabetes mellitus: The Framingham Heart Study. Circulation. 115 (2007), 1544–1550.
2. 2 Rydén, L., Grant, P.J., Anker, S.D., Berne, C., Cosentino, F., Danchin, N., et al., Authors/Task Force Members. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 34 (2013), 3035–3087.
3. 3 Pignone, M., Alberts, M.J., Colwell, J.A., Cushman, M., Inzucchi, S.E., Mukherjee, D., et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association and an expert consensus document of the American College of Cardiology Foundation. Circulation. 121 (2010), 2694–2701.
4. 4 Patrono, C., Aspirin as an antiplatelet drug. N Engl J Med. 330 (1994), 1287–1294.
5. 5 Eikelboom, J.W., Hankey, G.J., Thom, J., Bhatt, D.L., Steg, P.G., Montalescot, G., et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation. 118 (2008), 1705–1712.
6. 6 Egger, G., Burda, A., Obernosterer, A., Mitterhammer, H., Kager, G., Jürgens, G., et al. Blood polymorphonuclear leukocyte activation in atherosclerosis: effects of aspirin. Inflammation. 25 (2001), 129–135.
7. 7 Jy, W., Horstman, L.L., Jimenez, J.J., Ahn, Y.S., Biró, E., Nieuwland, R., et al. Measuring circulating cell-derived microparticles. J Thromb Haemost. 2 (2004), 1842–1851.
8. 8 Mallat, Z., Benamer, H., Hugel, B., Benessiano, J., Steg, P.G., Freyssinet, J.M., et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation. 101 (2000), 841–843.
9. 9 Suades, R., Padró, T., Vilahur, G., Badimon, L., Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques. Thromb Haemost. 108 (2012), 1208–1219.
10. 10 Namba, M., Tanaka, A., Shimada, K., Ozeki, Y., Uehata, S., Sakamoto, T., et al. Circulating platelet-derived microparticles are associated with atherothrombotic events: a marker for vulnerable blood. Arterioscler Thromb Vasc Biol. 27 (2007), 255–256.
11. 11 Sinning, J.M., Losch, J., Walenta, K., Böhm, M., Nickenig, G., Werner, N., Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J. 32 (2010), 2034–2041.
12. 12 Diamant, M., Nieuwland, R., Pablo, R.F., Sturk, A., Smit, J.W., Radder, J.K., Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation. 106 (2002), 2442–2447.
13. 13 Koga, H., Sugiyama, S., Kugiyama, K., Watanabe, K., Fukushima, H., Tanaka, T., et al. Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 45 (2005), 1622–1630.
14. 14 Leroyer, A.S., Isobe, H., Lesèche, G., Castier, Y., Wassef, M., Mallat, Z., et al. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol. 49 (2007), 772–777.
15. 15 Nieuwland, R., Berckmans, R.J., McGregor, S., Böing, A.N., Romijn, F.P., Westendorp, R.G., et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood. 95 (2000), 930–935.
16. 16 Wang, Y., Chen, L.M., Liu, M.L., Microvesicles and diabetic complications-novel mediators, potential biomarkers and therapeutic targets. Acta Pharmacol Sin. 35 (2014), 433–443.
17. 17 Sabatier, F., Darmon, P., Hugel, B., Combes, V., Sanmarco, M., Velut, J.G., et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes. 51 (2002), 2840–2845.
18. 18 Nomura, S., Inami, N., Shouzu, A., Urase, F., Maeda, Y., Correlation and association between plasma platelet-, monocyte- and endothelial cell-derived microparticles in hypertensive patients with type 2 diabetes mellitus. Platelets. 20 (2009), 406–414.
19. 19 Feng, B., Chen, Y., Luo, Y., Chen, M., Li, X., Ni, Y., Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus. Atherosclerosis. 208 (2010), 264–269.
20. 20 Zhang, X., McGeoch, S.C., Johnstone, A.M., Holtrop, G., Sneddon, A.A., MacRury, S.M., et al. Platelet-derived microparticle count and surface molecule expression differ between subjects with and without type 2 diabetes, independently of obesity status. J Thromb Thrombolysis. 37 (2014), 455–463.
21. 21 Omoto, S., Nomura, S., Shouzu, A., Nishikawa, M., Fukuhara, S., Iwasaka, T., Detection of monocyte-derived microparticles in patients with Type II diabetes mellitus. Diabetologia. 45 (2002), 550–555.
22. 22 Alonso, R., Andres, E., Mata, N., Fuentes-Jimenez, F., Badimon, L., Lopez-Miranda, J., et al. SAFEHEART Investigators. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 63 (2014), 1982–1989.
23. 23 Suades, R., Padró, T., Alonso, R., López-Miranda, J., Mata, P., Badimon, L., Circulating CD45+/CD3+ lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in familial hypercholesterolaemia patients. Thromb Haemost. 111 (2014), 111–121.
24. 24 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 324 (2002), 71–86.
25. 25 Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308 (1994), 81–106.
26. 26 Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ., 337, 2008, a1840.
27. 27 Sanmuganathan, P.S., Ghahramani, P., Jackson, P.R., Wallis, E.J., Ramsay, L.E., Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 85 (2001), 265–271.
28. 28 Ogawa, H., Nakayama, M., Morimoto, T., Uemura, S., Kanauchi, M., Doi, N., et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 300 (2008), 2134–2141.
29. 29 Duarte, R.C., Gonçalves, L.H., Campos, F.M., Filho, O.A., Alves, M.T., Fernandes, A.P., et al. Effect of acetylsalicylic acid on platelet activation and oxidative profile in a set of Brazilian patients with type 2 diabetes mellitus. Blood Coagul Fibrinolysis. 26 (2015), 123–130.
30. 30 Lubsczyk, B., Kollars, M., Hron, G., Kyrle, P.A., Weltermann, A., Gartner, V., Low dose acetylsalicylic acid and shedding of microparticles in vivo in humans. Eur J Clin Invest. 40 (2010), 477–482.
31. 31 Camargo, L.M., França, C.N., Izar, M.C., Bianco, H.T., Lins, L.S., Barbosa, S.P., et al. Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy. Braz J Med Biol Res. 47 (2014), 432–437.
32. 32 Biró, É., Sturk-Maquelin, K.N., Vogel, G.M.T., Meuleman, D.G., Smit, M.J., Hack, C.E., et al. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost. 1 (2003), 2561–2568.
33. 33 Angelillo-Scherrer, A., Leukocyte-derived microparticles in vascular homeostasis. Circ Res. 110 (2012), 356–369.
34. 34 Chironi, G., Simon, A., Hugel, B., Del Pino, M., Gariepy, J., Freyssinet, J.M., et al. Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol. 26 (2006), 2775–2780.